Influence of controlled rheumatoid arthritis on the action and disposition of verapamil: Focus on infliximab

Journal of Clinical Pharmacology

Volumn 49, Issue 3, 2009, Pages 301-311

  Ling, Spencer ^a   Lewanczuk, Richard Z ^b   Russell, Anthony S ^b   Ihejirika, Brendan ^a   Jamali, Fakhreddin ^a,b  

^a Faculty of Pharmacy and Pharmaceutical Sciences   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Inflammation; Infliximab; Remission; Rheumatoid arthritis; Verapamil

Indexed keywords

ANTIRHEUMATIC AGENT; APO VERAPAMIL; INFLIXIMAB; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERAPAMIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; MALE; PROTEIN BLOOD LEVEL; REMISSION; RHEUMATOID ARTHRITIS; STEREOSPECIFICITY;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NITRITES; TUMOR NECROSIS FACTOR-ALPHA; VERAPAMIL;

EID: 61449234078     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008328099     Document Type: Article

References (38)

1. Mayo PR, Skeith K., Russell AS, Jamali F. Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br J Clin Pharmacol. 2000 ; 50: 605-613.
2. Ling S., Jamali F. Effect of early phase adjuvant arthritis on hepatic P450 enzymes and pharmacokinetics of verapamil: an alternative approach to the use of an animal model of inflammation for pharmacokinetic studies. Drug Metab Dispos. 2005 ; 33: 579-586.
3. Schneider RE, Babb J., Bishop H., Mitchard M., Hoare AM Plasma levels of propranolol in treated patients with coeliac disease and patients with Crohn's disease. Br Med J. 1976 ; 2: 794-795.
4. Guirguis MS, Jamali F. Disease-drug interaction: Reduced response to propranolol despite increased concentration in the rat with inflammation. J Pharm Sci. 2003 ; 92: 1077-1084.
5. Kulmatycki KM, Abouchehade K., Sattari S., Jamali F. Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat. Br J Pharmacol. 2001 ; 133: 286-294.
6. Michaud K., Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007 ; 21: 885-906.
7. Maradit-Kremers H., Nicola PJ, Crowson CS, Ballman KV, Gabriel SE Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005 ; 52: 722-732.
8. McEntegart A., Capell HA, Creran D., Rumley A., Woodward M., Lowe GD Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxf). 2001 ; 40: 640-644.
9. Myllykangas-Luosujarvi R., Aho K., Kautiainen H., Isomaki H. Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol. 1995 ; 22: 1065-1067.
10. Pasceri V., Yeh ET A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation. 1999 ; 100: 2124-2126.
11. Sattar N., McCarey DW, Capell H., McInnes IB Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003 ; 108: 2957-2963.
12. Biasucci LM, Liuzzo G., Colizzi C., Maseri A. The role of cytokines in unstable angina. Expert Opin Investig Drugs. 1998 ; 7: 1667-1672.
13. Cesari M., Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003 ; 108: 2317-2322.
14. Ridker PM, Rifai N., Pfeffer M., Sacks F., Lepage S., Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000 ; 101: 2149-2153.
15. Kulmatycki KM, Jamali F. Drug disease interactions: role of inflammatory mediators in disease and variability in drug response. J Pharm Sci. 2005 ; 8: 602-625.
16. Daneshtalab N., Lewanczuk RZ, Russell A., Jamali F. Rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan. J Clin Pharmacol. 2004 ; 44: 245-252.
17. Daneshtalab N., Lewanczuk RZ, Russell AS, Jamali F. Losartan effect is not down-regulated by rheumatoid arthritis. J Clin Pharmacol. 2006 ; 46: 1344-1355.
18. Piquette-Miller M., Jamali F. Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. Drug Metab Dispos. 1995 ; 23: 240-245.
19. Kendall MJ, Quarterman CP, Bishop H., Schneider RE Effects of inflammatory disease on plasma oxprenolol concentrations. Br Med J. 1979 ; 2: 465-468.
20. Shibukawa A., Wainer IW Simultaneous direct determination of the enantiomers of verapamil and norverapamil in plasma using a derivatized amylose high-performance liquid chromatographic chiral stationary phase. J Chromatogr. 1992 ; 574: 85-92.
21. Grisham MB, Johnson GG, Lancaster JR, Jr. Quantitation of nitrate and nitrite in extracellular fluids. Methods Enzymol. 1996 ; 268: 237-246.
22. Abernethy DR, Schwartz JB, Todd EL, Luchi R., Snow E. Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses. Ann Intern Med. 1986 ; 105: 329-336.
23. Abernethy DR, Wainer IW, Longstreth JA, Andrawis NS Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. J Pharmacol Exp The. 1993 ; 266: 904-911.
24. Abernethy DR, Schwartz JB Verapamil pharmacodynamics and disposition in obese hypertensive patients. J Cardiovasc Pharmacol. 1988 ; 11: 209-215.
25. Sattari S., Dryden WF, Eliot LA, Jamali F. Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. Br J Pharmacol. 2003 ; 139: 945-954.
26. Hanafy S., Dagenais NJ, Dryden WF, Jamali F. Effects of angiotensin II blockade on inflammation-induced alterations of pharmacokinetics and pharmacodynamics of calcium channel blockers. Br J Pharmacol. 2008 ; 153: 90-99.
27. Clements JD, Jamali F. Pravastatin reverses the down-regulating effect of inflammation on β-adrenergic receptors: a disease-drug interaction between pravastatin, propranolol and inflammation. Vasc Pharmacol. 2006 ; 46: 52-59.
28. Charles P., Elliott MJ, Davis D., et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999 ; 163: 1521-1528.
29. Manicourt DH, Triki R., Fukuda K., Devogelaer JP, Nagant de Deuxchaisnes C., Thonar EJ Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis: relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum. 1993 ; 36: 490-499.
30. Arvidson NG, Gudbjornsson B., Elfman L., Ryden AC, Totterman TH, Hallgren R. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis. 1994 ; 53: 521-524.
31. Candon S., Mosca A., Ruemmele F., Goulet O., Chatenoud L., Cezard JP Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol. 2005 ; 118: 11-19.
32. Mangge H., Kenzian H., Gallistl S., et al. Serum cytokines in juvenile rheumatoid arthritis: correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum. 1995 ; 38: 211-220.
33. Corti A., Fassina G., Marcucci F., Barbanti E., Cassani G. Oligomeric tumour necrosis factor alpha slowly converts into inactive forms at bioactive levels. Biochem J. 1992 ; 284: 905-910.
34. De Groote D., Grau GE, Dehart I., Franchimont P. Stabilisation of functional tumor necrosis factor-alpha by its soluble TNF receptors. Eur Cytokine Netw. 1993 ; 4: 359-362.
35. Engelberts I., Stephens S., Francot GJ, van der Linden CJ, Buurman WA Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet. 1991 ; 338: 515-516.
36. Feldmann M., Maini RN The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxf). 1999 ; 38 (suppl 2). 3-7.
37. MacEwan DJ TNF ligands and receptors-a matter of life and death. Br J Pharmacol. 2002 ; 135: 855-875.
38. Belpaire FM, de Smet F., Chindavijak B., Fraeyman N., Bogaert MG Effect of turpentine-induced inflammation on the disposition kinetics of propranolol, metoprolol, and antipyrine in the rat. Fundam Clin Pharmacol. 1989 ; 3: 79-88.